pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,835 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1768Endpoints1377Fierce Biotech696BioSpace687BioPharma Dive522raps231onclive165fda recalls
therapy area
allOncology12276Rare Disease3178Immunology2859Cardiology2717Hematology2151Pulmonology2135Vaccines
  • 1834 measles letter highlights historic roots of today's anti-vaccine sentiment
    Jim Downs, a medical historian, examined a 1834 letter from Jane Butt in a London journal while at Yale's medical library, noting the date matches 192 years later. Butt described a measles outbrea…
    STAT · 11d agoNeutral↗ source
  • Genmab shares jump as petosemtamab plus Keytruda halves death risk in head-neck cancer trial
    Genmab reported that a late-stage study of its experimental antibody petosemtamab combined with Keytruda cut the risk of death by about 50 percent compared with Keytruda alone in patients with PD‑L…
    BioPharma Dive · 11d agoPositive readoutPositive↗ source
← prev
page 10 of 154
next →
111
fda medwatch109
globenewswire health73
fda press59
1787
Psychiatry & CNS1197
Ophthalmology1036
Endocrinology & Metabolism774
Pain768
Nephrology758
  • Eli Lilly beats Q3 revenue forecasts, lifts full-year outlook
    Eli Lilly reported third-quarter revenue of $24.4 billion, roughly $2 billion above analysts' expectations. The outperformance underscores the company's strong position, driven in part by its GLP-…
    Endpoints · 12d agoEarningsPositive↗ source
  • Labor Dept finalizes PBM disclosure rule to boost transparency for self-insured employers
    The U.S. Labor Department has finalized a rule that will require pharmacy benefit managers to disclose detailed fee and compensation information to self-insured employer clients, with the requireme…
    BioPharma Dive · 11d agoRegulatoryNeutral↗ source
  • Voters demand action on soaring health-care costs, boosting support for Medicare for All
    Recent polls show Americans increasingly worried about the rising cost of health care, with many saying it is their top financial concern. Voter anger is directed at politicians, who are seen as f…
    STAT · 12d agoNegative↗ source
  • Bristol Myers Squibb emphasizes pipeline strength and later-stage partnership focus amid patent cliff concerns
    Bristol Myers Squibb used its latest earnings call to outline how it plans to address an upcoming patent cliff that threatens revenue from several key products. Executives said the company is rely…
    Endpoints · 11d agoEarningsPositive↗ source
  • Merck R&D chief says company has outpaced rivals with its sac-TMT cancer platform
    Dean Li, the head of Merck Research Laboratories, said the company believes its sac-TMT cancer program gives it a competitive edge over other firms developing next-generation oncology therapies. T…
    Endpoints · 11d agoPositive↗ source
  • Federal rule forces PBMs to disclose fees and rebates to employers
    The Trump administration finalized a regulation that will require pharmacy benefit managers (PBMs) to reveal the various fees and compensation they receive from drugmakers, consultants and other pa…
    STAT · 11d agoRegulatoryPositive↗ source
  • UK secures £500m biopharma investment as Vertex commits over £300m to new Oxford R&D hub, while Teva plans New Jersey plant closure
    The UK government’s autumn budget has attracted about £500 million in new biopharma commitments, signalling strong support for the sector. Vertex Pharmaceuticals disclosed that it will put more th…
    Endpoints · 11d agoDealNeutral↗ source
  • Ono Pharma’s endocannabinoid drug ONO-1110 fails five Phase 2 trials, prompting broader concerns
    Ono Pharma reported that its experimental endocannabinoid modulator ONO-1110 did not achieve the primary efficacy endpoint in five separate Phase 2 clinical trials. The failures span multiple indi…
    Endpoints · 11d agoNegative readoutNegative↗ source
  • Genmab shares climb after head-and-neck cancer data as Iovance and Coherus stocks fall
    Genmab's shares moved higher after the company released data from a head‑and‑neck cancer trial, which investors interpreted as a positive signal for the drug's potential. In contrast, Iovance and…
    Endpoints · 11d agoPositive readoutNeutral↗ source
  • Big tech and startups are building personal AI agents to analyze patients’ medical records
    In a recent column the author notes that personal artificial-intelligence agents are poised to enter the healthcare arena. Large technology firms and emerging startups are creating platforms that…
    Endpoints · 11d agoNeutral↗ source
  • Vertex kidney disease drug faces infection risk scrutiny ahead of FDA decision
    Vertex's kidney disease therapy is expected to receive FDA approval, with the agency's decision scheduled for Nov 30. A previously undisclosed pause rule has drawn attention, raising concerns abou…
    STAT · 12d agoRegulatoryNeutral↗ source
  • Anthropic outlines biopharma strategy ahead of potential record-size IPO
    Anthropic, the AI startup that recently filed paperwork for what could become the largest initial public offering in business history, used its AI Day event to detail its biopharma ambitions. The…
    Endpoints · 12d agoNeutral↗ source
  • Flagship Pioneering merges three portfolio companies to boost AI drug discovery
    Flagship Pioneering, a biotech incubator based in Cambridge, Massachusetts, announced it is merging three of its portfolio companies into a single organization. The consolidation includes a compan…
    Endpoints · 12d agoDealPositive↗ source
  • Flagship Pioneering merges three biotech startups to launch AI-driven drugmaker Etcelera
    Flagship Pioneering announced the creation of Etcelera Therapeutics by merging three of its portfolio companies - Etiome, Cellarity and Empress Therapeutics. The new venture will combine artificia…
    BioPharma Dive · 12d agoDealPositive↗ source
  • New tumor atlas reveals why colorectal cancer is more aggressive in younger patients
    Researchers have created a new atlas that catalogs 189 colorectal tumor samples from patients aged in their 20s to 90s, aiming to clarify why cancers that arise early are harder to treat. The coll…
    STAT · 12d agoPositive↗ source
  • Eli Lilly leans on cash-pay model to grow obesity drug sales in US and overseas
    Eli Lilly has observed that patients in the United States are prepared to pay several hundred dollars each month for treatments targeting obesity. The company has focused on a cash-pay approach, s…
    Endpoints · 11d agoNeutral↗ source
  • Dren Bio secures $350 million to advance blood-cancer therapy toward 2027 launch
    Dren Bio, a California biotech firm, announced it has closed a financing round that raised $350 million. The funding will be directed toward developing its lead blood‑cancer drug, with the company…
    Endpoints · 12d agoDealPositive↗ source
  • Treasury's Proposed China Investment Rule Sparks Debate Over Licensing Exemptions
    The U.S. Treasury Department recently proposed a rule that would limit American investment in Chinese biotechnology companies, prompting immediate discussion among industry stakeholders. Commentat…
    STAT · 12d agoRegulatoryNeutral↗ source
  • Medline orders removal of all brand beds and accessories over fire and asphyxiation hazards
    Medline has issued an urgent field safety notice indicating that all of its branded hospital beds and related components must be removed or corrected because of identified safety risks. The FDA’s…
    fda medwatch · 12d agoRegulatoryNegative↗ source
  • Michigan Senate candidate El-Sayed rebuts RFK Jr. and highlights FDA's new enforcement discretion on peptide drugs
    Abdul El-Sayed, the Democratic Senate hopeful in Michigan, pushed back against recent statements made by RFK Jr., defending his own health-care positions and emphasizing his background as an immigr…
    STAT · 11d agoRegulatoryNeutral↗ source
  • Rising employer health premiums pressure workers as industry resists change
    Workers are currently choosing health plans for the upcoming year as average family premiums for employer coverage climb to $28,303 in 2026, a 28% increase over the past five years. Employers cont…
    STAT · 12d agoNegative↗ source
  • AI as partner, competitor or crutch? Biologists weigh benefits and risks
    In a recent STAT+ opinion, UC Davis cell biology professor Paul Knoepfler discusses how artificial intelligence is reshaping biomedical research. He acknowledges AI's ability to accelerate experim…
    STAT · 12d agoNeutral↗ source
  • Federal judge blocks narrow Medicaid frailty definition, expanding work-requirement exemptions
    Federal judge Richard D. Stearns in Massachusetts issued a permanent injunction against the new federal definition of “medical frailty” used to limit Medicaid work‑requirement exemptions. The judg…
    STAT · 11d agoRegulatoryNeutral↗ source